Published Studies Related to Ipratropium (Ipratropium Nasal)
The effect of administrative cessation of the use of ipratropium bromide in the treatment of acute asthma attacks in the emergency department. [2011.12]
Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. [2011.04]
BACKGROUND: The combination of inhaled beta(2) agonists and anticholinergics is recommended for children with acute asthma, although there are few randomized controlled trials. The aim of the study was to determine whether salbutamol plus ipratropium bromide improves oxygenation and lung function and reduces the frequency of hospitalization in children with asthma crises... CONCLUSIONS: Salbutamol plus ipratropium bromide improves lung function in asthmatic children with moderate to severe asthma crises, independently of age. The effect is greater in children with severe crises, with a substantial reduction in the need for hospitalization.
Levalbuterol versuss levalbuterol plus ipratropium in the treatment of severe acute asthma. [2010.12]
BACKGROUND: The National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3 guidelines advise the addition of ipratropium bromide to short-acting beta-agonist therapy for the treatment of patients with severe acute asthma exacerbation... CONCLUSION: We were unable to demonstrate superiority of adding ipratropium to levalbuterol in alleviating obstruction as measured by FEV or in decreasing the need for hospitalization among adult patients presenting to the ED with acute severe asthma exacerbation.
Functional response to inhaled salbutamol and/or ipratropium bromide in Ascaris suum-sensitised cats with allergen-induced bronchospasms. [2010.10]
Knowledge about the use of inhaled bronchodilators in cats with so-called 'feline asthma' is limited and relies on the experience of clinicians treating these patients. A randomised controlled four-way crossover study was therefore designed to compare the effects of salbutamol (SAL, 100 mug), ipratropium bromide (IB, 20 mug) and a combination of both (SAL/IB, 100 mug/20 mug), delivered through a pressurised metered-dose inhaler (pMDI) connected to a spacing chamber, on allergen-induced bronchospasms in five Ascaris suum (AS)-sensitised cats...
Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. [2010.08]
We compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and ipratropium Respimat inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-group, active-controlled study...
Clinical Trials Related to Ipratropium (Ipratropium Nasal)
Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes [Completed]
This will be a double-blind placebo-controlled study in which we plan to study 40
competitive endurance athletes. We will conduct an exercise test to evaluate maximal oxygen
uptake and 2 exercise challenge tests to provoke EIA. Prior to the exercise challenge tests
the athletes will randomly receive inhaled placebo or inhaled ipratropium bromide. We will
compare the athletes' airway response to the exercise challenge with and without the active
Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients [Completed]
The objectives of this study are to assess the effect of salbutamol in comparison with
ipratropium bromide on the geometry of central and peripheral airways and to correlate
spirometric indices with the Computational Fluid Dynamics (CFD) based calculated airway
volumes and resistances for both compounds.
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENTďż˝ Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Completed]
The objective of this study was to determine the pharmacokinetic comparability of 84 µg
ipratropium bromide HFA-134a inhalation aerosol and 84 µg ATROVENT® CFC Inhalation Aerosol
in COPD patients
A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation [Completed]
This is a double blind, controlled clinical trail testing whether three doses of 1. 25 mg of
nebulized levalbuterol in combination with three doses of 0. 5mg of nebulized ipratropium
will lead to greater bronchodilation than that achieved by three doses of nebulized 1. 25 mg
of levalbuterol alone every 20 minutes.
The primary hypothesis of this study is that three doses of 1. 25 mg of nebulized
levalbuterol in combination with three doses of 0. 5mg of nebulized ipratropium will lead to
greater bronchodilation than that achieved by three doses of nebulized 1. 25 mg of
levalbuterol alone every 20 minutes. The secondary hypothesis is that the treatment
combination of levalbuterol and ipratropium will lead to fewer hospitalizations than
levalbuterol alone in patients with acute asthma exacerbation. Other secondary objectives
include (1) evaluating the relationship between baseline (S)- albuterol levels and (R)-
albuterol levels on presentation and FEV1, (2) the relationship between baseline (S)-
albuterol levels and (R)- albuterol levels on presentation and change in FEV1,(3) time to
event analysis for an improvement of 15%, 20%, 30%, 40%, and 50% in FEV1 from initial
presentation value, (4) analysis of FEV1 at discharge.
Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease [Completed]
The primary objective of this study was to compare the long-term (12-week) bronchodilator
efficacy and safety of ipratropium bromide / salbutamol combination administered by the
Respimat® 40 mcg / 200 mcg (one inhalation q. i.d.) to COMBIVENT Inhalation Aerosol (two
inhalations q. i.d.), ipratropium bromide Respimat® (one inhalation q. i.d.) and Placebo
formulations of each in patients with Chronic Obstructive Pulmonary Disease (COPD). An
additional objective was to show the superiority of Combivent Respimat as compared to
ipratropium bromide (40 mcg) Respimat. Steady state pharmacokinetics over one dosing
interval following four weeks of therapy were also characterized.